Telix Pharmaceuticals reported full-year 2025 revenue of US$803.8 million, up 56% year over year, and issued 2026 guidance of US$950–970 million. Growth was fueled by continued uptake of its PSMA PET portfolio, the U.S. launch of Gozellix, and first full-year contribution from the RLS Radiopharmacies network. The company paired commercial momentum with late-stage pipeline progress, including European filing for Pixclara (TLX101-PX), alignment with FDA on a BLA resubmission path for Zircaix (TLX250-PX), and advancement of multiple radioligand therapeutics across prostate, kidney, and brain cancers.
The strategic signal is unambiguous: Telix is attempting to become a fully integrated radiopharma platform spanning diagnostics, therapeutics, and manufacturing. The immediate question for Commercial and Medical Affairs leaders is whether the company can translate its imaging-installed base and radiopharmacy footprint into durable therapy share before larger players consolidate the field, while absorbing the near-term margin trade-offs of building infrastructure and accelerating R&D.
Precision medicine remained the cash engine, with segment revenue up 22% and gross margin steady at 64%. Segment adjusted EBITDA rose to US$216.4 million, even as selling and marketing spend increased to support new launches and global scale-out. The Gozellix debut complements resilient Illuccix volumes and sets up a broader PSMA franchise strategy that could deepen HCP familiarity, streamline access workflows, and strengthen the diagnostic-to-therapy cascade crucial for payer acceptance and treatment throughput. Preparations for European Illuccix and future diagnostic launches suggest Telix intends to defend share through label expansion and operational reliability rather than price concessions.
Manufacturing and distribution were materially reshaped by RLS. The radiopharmacy network delivered US$238.4 million of segment revenue and turned positive on adjusted EBITDA, underscoring the value of last‑mile control in a modality where dose timing, site readiness, and isotope logistics dictate real-world utilization. With additional facilities in the U.S., Europe, Australia, and Japan, Telix is hedging against global constraints in Lu‑177 and Ac‑225 supply chains and positioning for faster turnaround times that directly influence clinic scheduling, patient experience, and payer perception of service reliability.
On the therapeutics front, Telix invested US$98 million to push three programs into pivotal territory and opened two first-in-human studies in targeted alpha therapy. The ProstACT phase 3 for TLX591‑TX in mCRPC expanded into its randomized stage, LUTEON initiated for TLX250‑TX in metastatic clear cell RCC alongside combination exploration, and the IPAX‑BRIGHT pivotal trial for TLX101‑TX in recurrent glioblastoma received regulatory clearance. Early alpha programs in PSMA and CAIX aim at differentiated efficacy in resistant disease but will demand rigorous Medical Affairs engagement on dosimetry, safety monitoring, and evidence generation to sway oncologists and radiation safety committees.
Regulatory execution will be the key 2026 swing factor. Telix indicates alignment with FDA on comparability for the Zircaix BLA resubmission, a frequent stumbling block when scaling from clinical to commercial manufacturing in radiopharma. European filing for Pixclara and a near-term U.S. NDA set up dual diagnostic catalysts, while the company’s decision to pre-build Zircaix inventory signals launch readiness and confidence in approval timing. The guidance uplift, paired with a planned US$200–240 million in R&D spend, implies an expectation of incremental product revenue beyond the current portfolio.
Radiopharma is in an arms race marked by capacity build-outs, isotope partnerships, and big-pharma consolidation, and the winners will marry supply certainty with compelling outcomes and clean reimbursement pathways. The coming year will test whether Telix’s vertical model can sustain near‑billion‑dollar revenue while converting diagnostic leadership into therapy adoption at scale—and whether early alpha readouts can create enough clinical separation to hold off deep-pocketed competitors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
